Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054543 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marek Drozdzik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Hepatitis C. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Cracow, Poland, Minister of Science and Higher Education (Regional Initiative of Excellence" in 2019-2022, Poland,, Minister of Science and Higher Education.
Abstract (Originalsprache)
Hepatic drug metabolizing enzymes (DMEs), whose activity may be affected by liver diseases, are major determinants of drug pharmacokinetics. Hepatitis C liver samples in different functional states, i.e., the Child–Pugh class A (n = 30), B (n = 21) and C (n = 7) were analyzed for protein abundances (LC-MS/MS) and mRNA levels (qRT-PCR) of 9 CYPs and 4 UGTs enzymes. The protein levels of CYP1A1, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 were not affected by the disease. In the Child–Pugh class A livers, a significant up-regulation of UGT1A1 (to 163% of the controls) was observed. The Child–Pugh class B was associated with down-regulation of the protein abundance of CYP2C19 (to 38% of the controls), CYP2E1 (to 54%), CYP3A4 (to 33%), UGT1A3 (to 69%), and UGT2B7 (to 56%). In the Child–Pugh class C livers, CYP1A2 was found to be reduced (to 52%). A significant trend in down-regulation of the protein abundance was documented for CYP1A2, CYP2C9, CYP3A4, CYP2E1, UGT2B7, and UGT2B15. The results of the study demonstrate that DMEs protein abundances in the liver are affected by hepatitis C virus infection and depend on the severity of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland.
- Department of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17489 Greifswald, Germany.
- Department of General and Transplantation Surgery, County Hospital, 71-455 Szczecin, Poland.
- Department of Mechatronics, West Pomeranian University of Technology, 70-310 Szczecin, Poland.
- Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 71-455 Szczecin, Poland.
- Laboratory of Pharmacodynamics, Pomeranian Medical University, 71-899 Szczecin, Poland.
ORCID-Profile: Marek Drozdzik, Joanna Lapczuk-Romanska, Christoph Wenzel, Arkadiusz Parus, Marta Syczewska, Stefan Oswald
Förderung
- National Science Centre, Cracow, Poland
- Minister of Science and Higher Education (Regional Initiative of Excellence" in 2019-2022, Poland,
- Minister of Science and Higher Education
Zitieren
APA
Drozdzik, M., Lapczuk-Romanska, J., Wenzel, C., Skalski, L., Szeląg-Pieniek, S., Post, M., Parus, A., Syczewska, M., Kurzawski, M., & Oswald, S. (2023). Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054543
Vancouver
Drozdzik M, Lapczuk-Romanska J, Wenzel C, Skalski L, Szeląg-Pieniek S, Post M, et al. Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054543
BibTeX
@article{Drozdzik2023,
author = {Drozdzik, Marek and Lapczuk-Romanska, Joanna and Wenzel, Christoph and Skalski, Lukasz and Szeląg-Pieniek, Sylwia and Post, Mariola and Parus, Arkadiusz and Syczewska, Marta and Kurzawski, Mateusz and Oswald, Stefan},
title = {Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054543}
}
EUVIMED